Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
Status:
Recruiting
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in
treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by
blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is
engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib may enhance
the efficacy of axicabtagene ciloleucel in treating patients with B-cell lymphoma.